BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in NHL

• First data for the SC arm: 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients.
• Further updates from the IV arm; a fifth CR has been observed, adding to a total of 5 CR, 1 PR and 6 SD out of 17 evaluable patients.
• Data to be presented at the European Hematology Association, June 13-16, 2024.
• BI-1206 is developed to re-establish the clinical effect of existing cancer treatments such as rituximab and is evaluated as both intravenous (IV) and subcutaneous (SC) administration.
• Phase 2a trial plans to include a triple combination with BI-1206, rituximab and acalabrutinib.

LUND, SE / ACCESSWIRE / May 14, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that promising clinical data for BI-1206 in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), dosed in combination with rituximab, will be presented in a poster at the European Hematology Association congress held in Madrid, Spain from June 13-16, 2024.

"We are pleased to share further validating Phase 1/2a data for BI-1206 in NHL during EHA. There is a high unmet need to develop treatments that can overcome resistance and improve the durability of responses to rituximab, an essential part of NHL treatment. We believe BI-1206 has the potential to meet this need," said Martin Welschof, Chief Executive Officer of BioInvent. "To identify the best options and meet the needs of clinicians and patients, we are evaluating BI-1206 administration as both IV and SC. IV dosing so far has produced response rates of a 35% ORR (overall response rate), 29% CRR (cumulative response rate) and 71% DCR (disease control rate), and we see promising early efficacy data from the subcutaneous dosing. In addition, we report an ORR of 56% in the subset of patients with follicular lymphoma (FL). Based on these encouraging results, we plan to initiate a Phase 2a study arm where the BTK inhibitor, acalabrutinib (Calquence), will be added to the rituximab and BI-1206 combination, which should further increase response rates."